The U.S. National Nanotechnology Initiative has updated its Environmental Health and Safety strategy to address ongoing challenges and emerging nanotechnology applications. The strategy emphasises responsible innovation and highlights the need for collaborative actions to address concerns related to the impact of engineered nanomaterials on human health and the environment.

Scientists from the public, private and philanthropic sectors involved in the Nano4EARTH initiative have identified key research directions to maximise the impact of nanotechnology in addressing climate change. They focus on enhancing energy storage, reducing industrial carbon emissions and improving efficiency in industrial processes.

Lipid nanoparticles (LNPs) are a groundbreaking delivery system for mRNA vaccines, such as those used for COVID-19. Now, they are pivotal in developing a range of new vaccines and gene therapies. The European Medicines Agency (EMA) and the European Pharmacopoeia are actively updating guidelines and quality requirements to ensure the safe and effective use of LNP-based medicine.

A recent EU ON opinion highlights the potential of advanced materials to support sustainability goals while acknowledging their human health and environmental risks. The European Commission’s 2024 communication emphasises the need for Safe-and-Sustainable-by-Design (SSbD) principles to ensure safety and sustainability.

The degradation of two-dimensional (2D) materials throughout their life cycle can result in the formation of degradation products with different properties and effects on human health and the environment than the original materials.

The European Commission (EC) intends to establish a digital infrastructure for advanced materials called the ‘Materials Commons’. This initiative intends to enhance the design, development, and testing of advanced materials. A key aspect of the platform will involve the use of artificial intelligence tools, which can potentially be used for optimized hazard and risk assessment of advanced materials.

A recent critical perspective argues that nanomaterials should be regulated as biological rather than chemical entities. The researchers emphasise the importance of using existing knowledge about the biological interactions of nanomaterials and their impact on human health and the environment. The authors list various well-known challenges regarding the safety assessment of nanomaterials.

The European Food Safety Authority (EFSA) has introduced new guidance for evaluating nanoparticles in food that may dissolve in lipids before consumption. By using the 1-octanol-water partition coefficient (KOW) method nanospecific considerations for safety assessments may potentially be waived.

Titanium dioxide (TiO2), previously banned as a food additive (E 171) in 2022 due to safety concerns, is used in medicines as an excipient. French scientists have estimated the intake of TiO2 from oral medications, finding that 54% contained TiO2, with an average daily intake of 1.71 mg. This is lower compared to the exposure from food when E 171 was still allowed.

Ex vivo exposure of human placentas to realistic concentrations of titanium dioxide (TiO2) and silicium dioxide (SiO2) nanoparticles affect placental protein secretion, which slowed the growth of new blood vessels in an in vitro model. Current regulatory guidelines do not sufficiently address placental toxicity, highlighting the need for improved testing methods to evaluate the reproductive and developmental toxicity of nanomaterials.